Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions

被引:17
|
作者
Gharavi, Robert [1 ,2 ]
Hedrich, William [1 ]
Wang, Hongbing [1 ]
Hassan, Hazem E. [1 ,3 ]
机构
[1] Univ Maryland, Dept Pharmaceut Sci, Sch Pharm, Baltimore, MD 21201 USA
[2] MedImmune, Clin Dev, Gaithersburg, MD 20878 USA
[3] Helwan Univ, Dept Pharmaceut & Ind Pharm, Fac Pharm, Cairo, Egypt
关键词
opioid abuse; opioid DDI; opioid drug transporters; opioids and P-gp; BLOOD-BRAIN-BARRIER; ORGANIC CATION TRANSPORTERS; P-GLYCOPROTEIN EXPRESSION; LONG QT SYNDROME; IN-VITRO; GENETIC POLYMORPHISMS; METHADONE PHARMACOKINETICS; MORPHINE PHARMACOKINETICS; CYTOCHROME P4503A; RENAL CLEARANCE;
D O I
10.1007/s11095-015-1711-5
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Opioid-related deaths, abuse, and drug interactions are growing epidemic problems that have medical, social, and economic implications. Drug transporters play a major role in the disposition of many drugs, including opioids; hence they can modulate their pharmacokinetics, pharmacodynamics and their associated drug-drug interactions (DDIs). Our understanding of the interaction of transporters with many therapeutic agents is improving; however, investigating such interactions with opioids is progressing relatively slowly despite the alarming number of opioids-mediated DDIs that may be related to transporters. This review presents a comprehensive report of the current literature relating to opioids and their drug transporter interactions. Additionally, it highlights the emergence of transporters that are yet to be fully identified but may play prominent roles in the disposition of opioids, the growing interest in transporter genomics for opioids, and the potential implications of opioid-drug transporter interactions for cancer treatments. A better understanding of drug transporters interactions with opioids will provide greater insight into potential clinical DDIs and could help improve opioids safety and efficacy.
引用
收藏
页码:2477 / 2502
页数:26
相关论文
共 50 条
  • [21] Pharmacogenomics and Drug Discovery: Impact of Transporter-mediated Disposition and Interaction in Chemotherapy
    Tsuji, Akira
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2005, 26 : S9 - S10
  • [22] Response to the Comment on the Article "Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions"
    Varma, Manthena V. S.
    Lai, Yurong
    Feng, Bo
    Litchfield, John
    Goosen, Theunis C.
    Bergman, Arthur
    PHARMACEUTICAL RESEARCH, 2013, 30 (06) : 1469 - 1470
  • [23] Response to the Comment on the Article “Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions”
    Manthena V. S. Varma
    Yurong Lai
    Bo Feng
    John Litchfield
    Theunis C. Goosen
    Arthur Bergman
    Pharmaceutical Research, 2013, 30 : 1469 - 1470
  • [24] Renal Transporter-Mediated Drug-Drug Interactions: Are They Clinically Relevant?
    Lepist, Eve-Irene
    Ray, Adrian S.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 : S73 - S81
  • [25] Transporter-mediated drug-herb and drug-food interactions
    Morris, Marilyn E.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [26] In vitro evaluation of potential transporter-mediated drug interactions of evogliptin
    Lee, Dae Y.
    Chae, Hye W.
    Shim, Hyun J.
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2017, 38 (06) : 398 - 403
  • [27] Transporter-Mediated Drug Delivery
    Gyimesi, Gergely
    Hediger, Matthias A.
    MOLECULES, 2023, 28 (03):
  • [28] Placental transporter-mediated drug interactions and offspring congenital anomalies
    Ellfolk, Maria
    Tornio, Aleksi
    Niemi, Mikko
    Leinonen, Maarit K.
    Lahesmaa-Korpinen, Anna-Maria
    Malm, Heli
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (05) : 868 - 879
  • [29] Use of PET Imaging to Evaluate Transporter-Mediated Drug-Drug Interactions
    Langer, Oliver
    JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 : S143 - S156
  • [30] Prediction of Transporter-Mediated Drug-Drug Interactions Using Endogenous Compounds
    Fromm, M. F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 92 (05) : 546 - 548